

This is a repository copy of *Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/184236/>

Version: Published Version

Article:

Dai, Wei Fang, Beca, Jaclyn M, Nagamuthu, Chenthila et al. (6 more authors) (2022) Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer. JAMA network open. e2145460. ISSN: 2574-3805

<https://doi.org/10.1001/jamanetworkopen.2021.45460>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Supplementary Online Content

Dai WF, Beca JM, Nagamuthu C, et al. Comparative effectiveness and safety of pertuzumab and trastuzumab plus chemotherapy vs trastuzumab plus chemotherapy for treatment of metastatic breast cancer. *JAMA Netw Open*. 2022;5(2):e2145460. doi:10.1001/jamanetworkopen.2021.45460


eFigure. Kaplan-Meier Overall Survival Curves in the Propensity Score–Matched Cohort for Patients Who Are Younger Than 65 Years and for the CLEOPATRA Trial for Patients of All Ages

eTable 1. Baseline Characteristics for a Subcohort of Patients Who Are Younger Than 65 Years

eTable 2. Sensitivity Analysis

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Kaplan-Meier Overall Survival curves in the propensity-score matched cohort for patients who are younger than 65 years and for the CLEOPATRA trial for patients of all ages



eTable 1: Baseline characteristics for a sub cohort of patients who are younger than 65 years

Covariates	Propensity Score Matched Cohort		
	Pertuzumab (n = 386)	Controls (n = 386)	Std. Diff
Age at index date, Median (range)	52 (47 – 58)	52 (45 – 59)	0.05
LHIN, N (%)			
Region 1	15 (3.9)	13 (3.4)	0.03
Region 2	36 (9.3)	32 (8.3)	0.04
Region 3	21 (5.4)	19 (4.9)	0.02
Region 4	33 (8.5)	31 (8.0)	0.02
Region 5	25 (6.5)	23 (6.0)	0.02
Region 6	43 (11.1)	50 (13.0)	0.06
Region 7	37 (9.6)	36 (9.3)	0.01
Region 8	38 (9.8)	44 (11.4)	0.05
Region 9	44 (11.4)	41 (10.6)	0.02
Region 10	18 (4.7)	19 (4.9)	0.01
Region 11	48 (12.4)	56 (14.5)	0.06
Region 12	<=10	<=10	0.02
Region 13	14 (3.6)	11 (2.8)	0.04
Region 14	<=5	<=5	0.06
Neighbourhood Income Quintile, N (%)			
Quintile 1 (lowest)	67 (17.4)	70 (18.1)	0.02
Quintile 2	77 (19.9)	89 (23.1)	0.08
Quintile 3	81 (21.0)	71 (18.4)	0.07
Quintile 4	81 (21.0)	75 (19.4)	0.04
Quintile 5 (highest)	80 (20.7)	81 (21.0)	0.01
Urban Residence, N (%)	338 (87.6)	337 (87.3)	0.01
Charlson's Score, N (%)			
0	228 (59.1)	224 (58.0)	0.02
1	<=20	<=20	0.02
2+	<=5	<=5	0
No hospitalization	133 (34.5)	139 (36.0)	0.03

Time between diagnosis to index date, y, Mean \pm SD	2.8 \pm 4.0	2.8 \pm 3.7	0.01
Cancer Stage, N (%)			
I	18 (4.7)	15 (3.9)	0.04
II	44 (11.4)	53 (13.7)	0.07
III	91 (23.6)	82 (21.2)	0.06
IV	151 (39.1)	147 (38.1)	0.02
Missing/Unknown	82 (21.2)	89 (23.1)	0.04
Prior hormonal therapy, N (%)	27 (7.0)	24 (6.2)	0.03
Prior bisphosphonate, N (%)	44 (11.4)	42 (10.9)	0.02
Prior adjuvant trastuzumab, N (%)	128 (33.2)	118 (30.6)	0.06
Prior any adjuvant treatment, N (%)	102 (26.4)	97 (25.1)	0.03
Prior neoadjuvant treatment, N (%)	50 (13.0)	44 (11.4)	0.05
Prior adjuvant radiation, N (%)	144 (37.3)	126 (32.6)	0.1
Prior breast cancer, N (%)	14 (3.6)	13 (3.4)	0.01
Prior other cancer, N (%)	13 (3.4)	13 (3.4)	0
Estrogen Receptor, N (%) ^a			
Negative	76 (49.0)	70 (52.8)	0.04
Positive	68 (51.0)	73 (47.2)	0.03
Progesterone Receptor, N (%) ^a			
Negative	95 (66.4)	92 (64.8)	0.02
Positive	48 (33.6)	50 (35.2)	0.02

^aPercentages based on known cases and controls

Legend: Std Diff = Standardized Differences

eTable 2: Sensitivity Analyses

	Pertuzumab Group Median OS, months (95% CI)	Control Groups Median OS, months (95% CI)	Hazard Ratio (95% CI)
Primary Analysis			
Propensity-score matched cohort (N = 1,166)	40.2 (35.6 – 47.8)	25.3 (22.8 – 27.6)	0.66 (0.57 – 0.79)
Scenario A: Patients with complete ER or PR status (N = 282)	48.7 (35.8 – NR)	27.2 (22.7 – 33.1)	0.62 (0.45 – 0.84)
Scenario B: Excluding vinorelbine (N = 924)	40.3 (35.7 – 48.7)	27.3 (25.2 – 32.9)	0.74 (0.62 – 0.88)
Scenario C: Patients less than 65 years old (N = 772)	48.5 (37.3 – NR)	26.6 (23.8 - 32)	0.59 (0.48 – 0.72)

Legend: NR = not reached

Note: The threshold of 65 years old was chosen because the median age in the cohort approximates that of the pivotal trial (median age = 54).